AUA 2023 Prostate Cancer

Viewing 1-20 of 65 articles

AUA 2023: Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-Risk Biochemically Recurrent Prostate Cancer: EMBARK

AUA 2023: Role and Extent of Pelvic Lymph Node Dissection in PSMA Era

AUA 2023: Single Port Robotic Assisted Radical Prostatectomy, Technical Point of View

AUA 2023: Infectious and Non-Infectious Complications Following Prostate Biopsy: A Randomized Clinical Trial

AUA 2023: Oligometastatic Disease—Who/Why for Directed Therapy

AUA 2023: Prostate Cancer in the Middle East

AUA 2023: Follow-Up Lecture: Somatic Testing — What’s the Difference? Why Bother?

AUA 2023: Next Generation Imaging Updates from the RADAR Group

AUA 2023: How to Select Appropriate Candidates in their 70’s for PSA Screening and Curative Treatment versus Observation Strategies

AUA 2023: Third Update: What is the Urologists Role for Theranostics?

AUA 2023: Stage and Grade Migration of Prostate Cancer During the COVID-19 Pandemic

AUA 2023: Trends in Definitive Therapy for Prostate Cancer During the COVID-19 Pandemic: A Grade-by-Grade- Analysis

AUA 2023: Is Learning Curve Important While Performing PSMA-PET? Analysis of Detection Rate According to Gleason Score and PSA in Two Timeframes at a Brazilian High-Volume Center

AUA 2023: PSA Screening: Proactive or Counterproductive?

AUA 2023: Racial Disparities in Future Development of Lethal Prostate Cancer Based on PSA Levels in Midlife

AUA 2023: Updated Progression-Free Survival from PRESTO: a Phase 3 Randomized Study of Androgen Annihilation for High-Risk Biochemically Relapsed Prostate Cancer (AFT-19)

AUA 2023: Artificial Intelligence-Enabled Automated Identification of Key Steps in Robotic-Assisted Radical Prostatectomy

AUA 2023: Second Update: Is Combination Therapy the New Standard of Care for Metastatic Castrate Resistant Prostate Cancer Patients?

AUA 2023: Prostate Cancer Guidelines — Where I See Progress and Help with My Practice

AUA 2023: First Update: Managing our Metastatic Hormone Sensitive Prostate Cancer Patients: Are We There Yet?

1
2
3
4